Inodilators in acute heart failure/cardiogenic shock
International registries report that between 12% and 20% of patients admitted to emergency departments with acute heart failure will receive inotropic medication. In this video, Professor Finn Gustafsson
reviews international guidelines on the use of inotropes in acute heart failure. He also describes comparator mortality data, and the unique profile of levosimendan, with its long-lasting active metabolite, OR 1986, and its lack of impact on beta-blocker therapy.
Dr Veli-Pekka Harjola
comments on the presentation at the end of the video and reiterates the importance of looking for the clinical signs of hyperperfusion (cold skin, mental disturbance, oliguria, increased lactate) that let you know when to treat a patient with acute heart failure and cardiogenic shock.